Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Operating Costs and Expenses:
General and administrative	$ 1,044	$ 1,431	$ 2,199	$ 3,051
Research and development	2,594	3,572	5,012	6,942
Total Operating Costs and Expenses	3,638	5,003	7,211	9,993
Loss from Operations	(3,638)	(5,003)	(7,211)	(9,993)
Other Income :
Change in fair value of warrant liability	0	783	0	3,438
Interest income	80	6	125	15
Total Other Income	80	789	125	3,453
Net Loss	(3,558)	(4,214)	(7,086)	(6,540)
Net Loss Attributable to Non-controlling Interest	27	17	43	26
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	(3,531)	(4,197)	(7,043)	(6,514)
Net Loss Attributable to Common Stockholders	$ (3,709)	$ (4,258)	$ (7,680)	$ (6,634)
Net Loss Per Share - Basic and Dilutive	$ (0.23)	$ (1.16)	$ (0.48)	$ (1.80)
Weighted average number of shares outstanding during the period - Basic and Dilutive	16,465,314	3,683,383	16,063,283	3,678,389
Series A Preferred Stock [Member]
Other Income :
Preferred Stock Dividends, Income Statement Impact	$ (61)	$ (61)	$ (122)	$ (120)
Series B Preferred Stock [Member]
Other Income :
Preferred Stock Dividends, Income Statement Impact	$ (117)	$ 0	$ (515)	$ 0